The principle of an increased immunogenicity of vaccines, by targeting them as immune complexes for robust phagocytosis by APCs, is not unique to tumor vaccines immunocomplexed with anti-Gal; it has been observed with a variety of antigens used as vaccines. This evidence concerns the gene GAL and neoplasm.